Altos Therapeutics (United States)
- h-index: 4
- Total citations: 32
- Total papers: 6
Recent papers from Altos Therapeutics (United States)
- Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of GastroparesisJournal of Experimental Pharmacology · 2022
- Evaluating the Safety, Tolerability, and Disposition of Trazpiroben, a D₂/D₃ Receptor Antagonist: Phase I Single‐ and Multiple‐Ascending Dose Studies in Healthy Japanese ParticipantsClinical Pharmacology in Drug Development · 2021
- Preclinical Evaluation of the Effects of Trazpiroben (TAK-906), a Novel, Potent Dopamine D2/D3 Receptor Antagonist for the Management of GastroparesisJournal of Pharmacology and Experimental Therapeutics · 2021
- Safety, Pharmacokinetics, and Pharmacodynamics of Trazpiroben (TAK‐906), a Novel Selective D₂/D₃ Receptor Antagonist: A Phase 1 Randomized, Placebo‐Controlled Single‐ and Multiple‐Dose Escalation Study in Healthy ParticipantsClinical Pharmacology in Drug Development · 2021